Neurovascular Devices Market Size, Share and Trends 2026 to 2035

What is the Neurovascular Devices Market Size?

The global neurovascular devices market size is calculated at USD 3.27 billion in 2025 and is predicted to increase from USD 3.54 billion in 2026 to approximately USD 7.12 billion by 2035, expanding at a CAGR of 8.09% from 2026 to 2035. The key players operating in the market are focused on adopting inorganic growth strategies like acquisition and merger to develop advance technology for manufacturing neurovascular devices which is estimated to drive the global neurovascular devices market over the forecast period.

Neurovascular Devices Market Key Takeaways

• North America dominated the neurovascular devices market with revenue share of 31% in 2025.
• Asia Pacific is expected to grow at a significant rate in the market during the forecast period.
• By device, the cerebral embolization and aneurysm coiling devices segment dominated the market with the largest share in 2024.
• By therapeutic application, stroke segment is expected to grow at significant rate during the forecast period.
• By size, the 0.021" segment dominated the market with the largest share in 2025.
• By end-use, the hospitals segment dominated the neurovascular devices market in 2025.

How Can AI Improve the Neurovascular Devices Industry?

AI can improve the accuracy and speed of diagnostics by analyzing medical images such as CT scans, MRIs, and angiograms. Machine learning algorithms can detect abnormalities like aneurysms, strokes, or other neurovascular diseases more quickly and accurately than traditional methods, aiding in early detection and treatment.

AI can assist in developing personalized treatment plans by analyzing patient data, including medical history, imaging results, and genetic factors. This can optimize surgical or endovascular interventions for better patient outcomes, reducing complications. AI can forecast patient outcomes and complications, helping healthcare providers make informed decisions. For example, it can predict the likelihood of a stroke or the risk of a clot forming post-surgery, enabling proactive care management.

Wearable AI devices can continuously monitor neurovascular health, offering real-time data to both patients and healthcare providers. This allows for better management of chronic conditions like hypertension, which is a risk factor for neurovascular events. AI can optimize clinical trial design by identifying the most suitable patients, predicting trial outcomes, and analyzing large datasets faster, thus accelerating the approval process for new neurovascular devices.

Neurovascular Devices Market Growth Factors

• The key players operating in the market are focused on geographic expansion and launching their medical device brand in other countries which is expected to drive the growth of the neurovascular devices market in the near future.
• Increasing focus on cost reduction and production efficiency can drive the specialty market growth further.
• Emerging markets and trends for neurovascular devices is expected to drive the growth of the global neurovascular devices market over the forecast period.
• Increasing regulatory support is estimated to drive the growth of the market over the forecast period.
• Increasing in adoption of the advanced technology for the production of neurovascular devices is estimated to drive the growth of the global neurovascular devices market in the near future.
• Technology advancements like development of minimally invasive devices that improve patient outcomes, has estimated to drive the growth of the market over the forecast period.
• Increasing demand for minimally invasive procedures has driven the growth of the neurovascular devices market in the near future.
• Rising investments in healthcare systems, particularly in developing countries, has estimated to drive the growth of the market.

Market Scope

Market Dynamics

Drivers

Technological Advancements

Neurovascular devices are driving the market with a profound shift toward minimally invasive procedures that present advantages such as shorter recovery time and reduced risk for complications. With continuous innovations in advanced devices, including stent retrievers, coils, and balloon angioplasty systems, the treatment methods evolve further to improve efficacy and patient outcomes. From the other end, advances in genetics and proteomics allow personalized neurovascular therapies to be developed, in which treatments are made to suit a patient's profile. These technological improvements fuel the incidence of the market by rendering it safer, more effective, and acceptable to patients.

Restraint

Regulatory Hurdles

On account of rigorous regulatory challenges, the neurovascular devices market has to undergo extensive testing, conduct clinical trials, and furnish copious documentation for the acceptance of all its products. The regulations are provided for the safety and efficacy, but they stretch the development cycle and costs for the manufacturers. Protracted approval periods could curtail the timely launch of innovative devices and, thus, diminish market agility geared toward emergent clinical needs. Regulatory complexity will continue to be another major hurdle, adversely affecting new entrants and established players alike, and thus the entire undertaking may suffer slowed growth.

Opportunity

Supportive Government Initiatives and Awareness Programs

Campaigns aimed at early diagnosis and treatment of neurovascular diseases. Investments in healthcare infrastructure to ensure access to advanced devices. Increasing government initiatives for early diagnosis of neurovascular disease has estimated to create lucrative opportunity for the growth of the neurovascular devices market in near future.

• For instance, in July 2024, The Alzheimer's Association International Conference (AAIC 2024), which will take place in Philadelphia, Pennsylvania, in 2024, will feature Neurophet, an artificial intelligence (Al) solution firm for brain disorders. Neurophet will introduce "NeurophetAQUA AD," a program for prescribing treatments for Alzheimer's disease (AD) and tracking their adverse effects, at the next AAIC. An integrated solution of state-of-the-art brain image analysis technologies for AD therapies is Neurophet AQUA AD. Currently, this system is getting ready for medical device certifications in Japan, the United States, and Korea.

Expansion of Hospital Services to Support Dominance in 2024

Hospitals segment dominated the neurovascular devices market globally. The primary cause of this segment's rise is the growing number of patients with neurovascular conditions, including arteriovenous malformation (AVM), brain aneurysms, ischemic and hemorrhagic stroke, and traumatic brain injury (TB1). For instance, in August 2024, the World Stroke Organization estimates that 1 in 4 adults over 25 will have a stroke at some point in their lives. It is estimated that 13.7 million people will have their first stroke each year, with 5.5 million of those individuals potentially losing their lives. It seems likely that the annual death toll will rise to 6.7 million if appropriate action is not taken. Furthermore, it is anticipated that the growing number of patients being admitted to hospitals as a result of operations, treatments, and therapies will boost market expansion. Therefore, the introduction of technologically sophisticated goods, the ensuing rise in the number of patients worldwide, and advantageous reimbursement policies are all significant aspects anticipated to support segment expansion.

Neurovascular Devices Market Segment Insights

[[segment_insights]]

Neurovascular Devices Market Regional Insights

[[regional_insights]]

Key Companies & Market Share Insights

The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved products. Moreover, they are also focusing on maintaining competitive pricing.

• In August 2020, Stryker Corporation a flow diverter named Surpass Evolve Flow Diverter, in the US after acquiring FDA approval.

The various developmental strategies like new product launches, acquisition, partnerships, mergers, and government policies foster market growth and offers lucrative growth opportunities to the market players.

Neurovascular Devices Market Companies

• Medtronic
• MicroPort Scientific Corporation
• Penumbra, Inc.
• Stryker Corporation
• Johnson & Johnson Services, Inc.
• MicroVention, Inc.
• Codman Neuro

Latest Announcements by the Industry Leaders

• In June 2024, Joan Kristensen, head of the Europe, Middle East and Africa region for Penumbra, Inc. said, “With five innovative devices introduced in Europe in a matter of months, our dedication to improving stroke care enables us to provide physicians with customised stroke solutions, she further adds, “In all modesty, Penumbra provides physicians with the widest aspiration thrombectomy stroke portfolio on the market.”

Recent Developments

• In July 2025, Q'Apel Medical received FDA clearance for its Zebra neurovascular access system, which is being prepared for a full US launch. Available in 6Fr and 7Fr sizes, it is intended for interventional devices in peripheral and neurovascular vasculature. (Source: https://neuronewsinternational.com)
• In February 2025, Johnson & Johnson MedTech launched the CEREGLIDE 92 Catheter System, a next-generation 092' catheter designed for facilitating the insertion and guidance of interventional devices in the neurovascular system. (Source: https://medicaldialogues.in)
• In 2024, CERENOVUS, Inc., a division of Johnson & Johnson MedTech*, announced the introduction of EMBOGUARDTMM, a next-generation balloon guide catheter intended for use in endovascular operations, including those involving patients who have had an acute ischemic stroke.
• In June 2024, MicroVention, Inc., a multinational neurovascular business and a fully owned subsidiary of Terumo Corporation, declared that the LVISTM EVO™ Intraluminal Support Device, which is intended to treat wide neck intracranial aneurysms, is now commercially available in the US. Since its release in 2019, LVIS EVO has sold more than 12,000 units in Europe.

Neurovascular Devices Market Segments Covered in the Report

[[segment_covered]]